drugset
drugset / Trial / NCT01408511

HPA Axis Study in Adults

NCT01408511 ↗

Phase 2 Completed 23 enrolled Bayer
NaSingle-groupOpen-labelTreatment

Summary

A multicenter, open-label study to evaluate the adrenal suppression potential of Mapracorat 0.1% ointment in adults with atopic dermatitis.

Timeline

Start
2011-07-19
Primary completion
2011-12-15
Completion
2011-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Mapracorat Small molecule 0.1 % Topical

Indications

atopic eczema